Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK similarity of ABP 234 and Keytruda in early-stage non-squamous NSCLC adjuvant setting
2023-508359-38-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3, randomised trial in Non-small cell lung cancer (NS-NSCLC) comparing ABP 234 with Keytruda (2 arms). Primary endpoint: Primary pharmacokinetic similarity endpoints. Planned start May 2024; status: authorised.
02
Drugs
pembrolizumababp 234
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2023-508359-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508359-38-00.